Boryung Corporation

003850KOSPIPharmaceuticals

Boryung Corporation (003850, KOSPI) reported KRW 1,017bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20238606840916549Consolidated
20241,01770701,164785Consolidated
20251,01765641,388846Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20237.9%4.7%60%7.3%
20246.9%6.8%67.4%8.9%
20256.4%6.3%60.9%7.6%

Revenue moved 18.4% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 762bn
Close priceKRW 8,880
Listed shares85,787,207
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)1,645
Women522 (31.7%)
Average tenure7.7 years
Annual pay, menKRW 77,764,000
Annual pay, womenKRW 59,788,000
Pay ratio, women to men76.9%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →